Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve 1. To consider and approve the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd has informed BSE that its Board of Directors will meet on Friday, 30th May 2025 at 5:00 p.m. at the registered office. The main item on the agenda is to consider and approve the audited financial results for the quarter and full year ended 31st March 2025, as required under SEBI's Listing Regulations. Any other business with the Chairman's permission may also be taken up. The trading window for promoters, directors, designated employees, and connected persons has been closed and will remain so until 48 hours after the results are announced.
This is a routine pre-results announcement and does not by itself move the stock. Investors should watch the actual audited Q4 and FY25 numbers when released on or after 30th May 2025 for any meaningful signals on profitability or business health.